Daiichi Sankyo struggles despite olmesartan growth
This article was originally published in Scrip
Executive Summary
Despite continued strength for the angiotensin II antagonist olmesartan (Benicar/Olmetec), a stronger yen, divestment of non-core operations and a change in year end at the company's European subsidiary all took their toll on Daiichi Sankyoin the first quarter, when total net sales slipped by 13% to ¥203.7 billion ($1.88 billion).